Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era

doi:10.3748/wjg.v29.i33.4942

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 33

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7920)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-6) series.

Item

Count

PDF

137

WORD

HTML

5541

Figures (1-1)

421

Tables (1-6)

456

Sum=6616

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

252

Download

597

Sum=849

Sep 7, 2023 (publication date) through Feb 18, 2025

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Sep 7, 2023; 29(33): 4942-4961
Published online Sep 7, 2023. doi: 10.3748/wjg.v29.i33.4942

Table 6 Recommendations for management strategy of hepatitis B virus-infected cancer patients receiving novel agents for hematological malignancies

Therapy	Chronic HBV infection	Past resolved HBV infection
CAR-T (e.g., axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel)	Antiviral prophylaxis	Antiviral prophylaxis
Bispecific antibodies (e.g., glofitamab, mosunetuzumab)	Antiviral prophylaxis	Antiviral prophylaxis
BTK inhibitors (e.g., ibrutinib, acalabrutinib, zanubrutinib)	Antiviral prophylaxis	Antiviral prophylaxis or monitoring and pre-emptive therapy¹
BCL-2 inhibitors (venetoclax)	Antiviral prophylaxis	Antiviral prophylaxis or monitoring and pre-emptive therapy¹
Anti-CD19 monoclonal antibody (blinatumumab)	Antiviral prophylaxis	Antiviral prophylaxis
Anti-CD22 monoclonal antibody (inotuzumab)	Antiviral prophylaxis	Antiviral prophylaxis
Anti-CD79 monoclonal antibody (polatuzumab)	Antiviral prophylaxis	Antiviral prophylaxis
Anti-CD38 monoclonal antibody (daratumumab)	Antiviral prophylaxis	Antiviral prophylaxis

¹Pre-emptive therapy is monitoring of serum hepatitis B virus DNA every 1-3 mo during and after immunosuppression, and starting antiviral therapy with entecavir or tenofovir in the case of detectable hepatitis B virus DNA levels.

HBV: Hepatitis B virus; CAR: Chimeric antigen receptor; BTK: Bruton tyrosine kinase; BCL: B-cell lymphoma.

Citation: Mak JWY, Law AWH, Law KWT, Ho R, Cheung CKM, Law MF. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era. World J Gastroenterol 2023; 29(33): 4942-4961
URL: https://www.wjgnet.com/1007-9327/full/v29/i33/4942.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i33.4942